Dizal Pharmaceutical Announces Uncertainty Regarding the Effectiveness of Its Licensing Agreement with AstraZeneca

Stock News07-15 17:05

Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib®. As of the date of the announcement's disclosure, the transaction still requires approval from the company's shareholders' meeting. Its final effectiveness is contingent upon meeting customary closing conditions and obtaining necessary approvals, including from antitrust regulatory authorities and other relevant agencies in overseas jurisdictions. There is uncertainty regarding whether the Licensing Agreement will ultimately come into effect.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197435491?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 17:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197435491","market":"other","top_or_hot":-1,"title":"Dizal Pharmaceutical Announces Uncertainty Regarding the Effectiveness of Its Licensing Agreement with AstraZeneca","media":"Stock News","content":"<p>Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib®. As of the date of the announcement's disclosure, the transaction still requires approval from the company's shareholders' meeting. Its final effectiveness is contingent upon meeting customary closing conditions and obtaining necessary approvals, including from antitrust regulatory authorities and other relevant agencies in overseas jurisdictions. There is uncertainty regarding whether the <b>Licensing Agreement</b> will ultimately come into effect.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Dizal Pharmaceutical Announces Uncertainty Regarding the Effectiveness of Its Licensing Agreement with AstraZeneca</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDizal Pharmaceutical Announces Uncertainty Regarding the Effectiveness of Its Licensing Agreement with AstraZeneca\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-07-15 17:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib®. As of the date of the announcement's disclosure, the transaction still requires approval from the company's shareholders' meeting. Its final effectiveness is contingent upon meeting customary closing conditions and obtaining necessary approvals, including from antitrust regulatory authorities and other relevant agencies in overseas jurisdictions. There is uncertainty regarding whether the <b>Licensing Agreement</b> will ultimately come into effect.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"688192","symbol_name":"迪哲医药-U","start_time":0,"source_url":"","article_id":"1197435491","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197435491","pubTimestamp":1784106339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","688192":"迪哲医药-U","BK0239":"医药制造","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A","AZN":"阿斯利康","LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4588":"碎股","BK4568":"美国抗疫概念","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","BK4007":"制药","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","BK1161":"生物科技","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","09939":"开拓药业-B","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK1515":"抗疫概念","LU0058720904.USD":"联博国际健康护理基金A","BK4585":"ETF&股票定投概念","BK1574":"生物医药B类股","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC"},"translate_title":"Dizal Pharmaceutical 宣布其与阿斯利康许可协议的有效性存在不确定性","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"688192":1,"09939":1,"AZN":1,"AZNH":1},"content_text":"Dizal Pharmaceutical Co.,Ltd. (SH: 688192) has issued a stock price fluctuation announcement. The company recently entered into a licensing agreement with AstraZeneca UK Limited, granting AstraZeneca the exclusive global rights to develop and commercialize Sunvozertinib®. As of the date of the announcement's disclosure, the transaction still requires approval from the company's shareholders' meeting. Its final effectiveness is contingent upon meeting customary closing conditions and obtaining necessary approvals, including from antitrust regulatory authorities and other relevant agencies in overseas jurisdictions. There is uncertainty regarding whether the Licensing Agreement will ultimately come into effect.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197435491","isCrawlerRequest":true}